+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the efficacy of sutetinib maleate capsules for treating participants with locally advanced or metastatic non-small cell lung cancer NSCLC that have uncommon EGFR mutations. Sutetinib is an investigational drug that works by irreversibly inhibiting the EGFR tyrosine kinase, a protein involved in cell growth and survival. The study focuses on how well sutetinib maleate capsules work specifically for this subgroup of NSCLC patients. Participants will receive sutetinib maleate capsules orally, preferably with food, at doses directed by the investigators. The treatment is given in 28-day cycles. This is an open-label, single-arm study where all participants will receive the investigational drug. The study is designed to assess both efficacy and safety over an extended period. During the study, participants will be closely monitored with assessments including tumor response evaluations using objective response rate ORR up to approximately 32 months after starting the drug. Additional measurements will include duration of response, disease control rate, progression-free survival, overall survival, and various pharmacokinetic parameters. Safety is carefully tracked through reports of adverse events and reactions. The total participation period may last up to about 32 months from the first dose.

Age: 18Years +All GendersPhase 2
24 locations
E

Actively Recruiting

Researchers are studying the use of albumin combined with endovascular treatment in patients who have an acute ischemic stroke in the anterior circulation. This trial is a prospective, multicenter, open-label, randomized controlled study aiming to determine the safety and effectiveness of adding albumin to the standard endovascular therapy for this condition. Patients will be selected based on specific criteria including stroke severity and imaging findings. Participants will be randomly assigned to one of two groups one receiving albumin along with endovascular treatment, and the other receiving only the recommended endovascular treatment. Albumin is given as a 25% human albumin intravenous infusion at a dose of 0.5gkg maximum 37.5g once initially and then daily for the next three days. Both groups will also receive acute stroke care and secondary prevention therapies according to current guidelines. During the study, participants will undergo initial imaging tests such as CT or MRI scans to confirm stroke location and exclude hemorrhage, along with laboratory tests and stroke severity assessments including the NIH Stroke Scale and modified Rankin Scale. Vital signs will be monitored, and patients will be followed for 90 days after randomization via telephone to evaluate their recovery and quality of life. The primary outcome is the proportion of patients achieving good functional status or returning to their baseline by 90 days.

Age: 18Years - 80YearsAll GendersPhase 3
61 locations
O

Actively Recruiting

This research aims to observe and evaluate the safety and effectiveness of Medtronic Neurovascular devices used in treating intracranial aneurysms and acute ischemic stroke. It is a prospective, multi-center, single-arm registry designed for ongoing product surveillance and periodic reporting. The study includes patients treated with market-approved Medtronic devices to gather real-world data on these conditions. Participants receive treatment involving embolization for intracranial aneurysms or revascularization for acute ischemic stroke using Medtronic devices. This observational registry collects data from patients undergoing these treatments without assigning specific interventions, reflecting routine clinical care practices. The study continues to enroll and monitor patients over an extended period. During participation, patients are observed and followed up to assess clinical success, defined as complete occlusion of the aneurysm without retreatment or significant artery narrowing at one year, and functional independence measured by the mRS score at 90 days. Researchers collect information from medical records and follow-up visits to monitor outcomes and safety. The study spans multiple years, with ongoing data collection up to August 2032.

Age: 18Years +All Genders
99 locations
S

Actively Recruiting

Researchers are evaluating normobaric hyperoxia NBO as a treatment for patients who have experienced an acute ischemic stroke and are transferred for endovascular thrombectomy EVT. The study aims to assess the effectiveness and safety of NBO in improving functional outcomes at 3 months after stroke. Stroke is a leading cause of death and disability, and although reperfusion treatments like thrombectomy improve blood flow, less than half of patients achieve favorable recovery. NBO is thought to protect the brain by rescuing hypoxic tissue and reducing damage processes, with advantages such as low cost and easy use. Participants will be randomly assigned to receive either NBO, which involves inhaling 100% oxygen alongside the best medical care, or best medical care alone. The study compares these two groups to see if NBO provides additional benefits. The treatment is given during the acute phase before or during transfer for EVT. The study includes a single-blind design and follows patients for outcomes over time. During the study, participants will have their disability level measured using the modified Rankin Scale at 90 days and one year after randomization. Other assessments include neurological function scores, imaging scans, infarct volume changes, and quality of life questionnaires at various time points. Safety and recovery progress are closely monitored throughout, with follow-up visits to track long-term effects. The total participation duration includes initial treatment and follow-up through one year.

Age: 18Years +All GendersPhase 3
112 locations
R

Actively Recruiting

Researchers are evaluating whether a real-time, algorithm-driven ventilation feedback system can improve lung-protective ventilation LPV in critically ill patients with acute respiratory distress syndrome ARDS or similar respiratory failure who are receiving invasive mechanical ventilation. The study compares this new technology against standard intensive care unit ICU care, aiming to increase the time patients maintain safe ventilation settings. The main goal is to see if this approach helps reduce ventilator-induced lung injury and improve outcomes over the first 72 hours of ventilation. Participants are randomly assigned to one of two groups the intervention group receives continuous respiratory waveform monitoring via a cloud-based system called RemoteVentilate ViewTM, which provides real-time alerts, 4-hour window checks, and daily summary reports to guide ventilator adjustments. The control group receives usual ICU care with standard ventilator monitoring but without structured feedback. Both groups continue to receive other treatments such as fluid management, sedation, and adjunct respiratory monitoring as decided by their clinical teams. During the study, participants are monitored closely with high-frequency data collection on ventilation parameters and patient-ventilator synchrony. Researchers measure the daily rate of lung-protective ventilation achievement over the first 72 hours, ventilator-free days at 28 days, ICU length of stay, inflammatory markers, and rates of complications like ventilator-associated pneumonia and barotrauma. Usability and workload for clinicians using the feedback system are also assessed. The total study period includes close monitoring throughout ICU care, with outcomes followed up to 28 days after enrollment.

Age: 18Years - 75YearsAll GendersPhase Not Applicable
1 location
P

Actively Recruiting

Researchers are studying children with short stature who were born small for gestational age SGA to evaluate the safety and effectiveness of Inpegsomatropin injection compared with recombinant human growth hormone rhGH. This Phase III, multicenter, randomized clinical trial aims to better understand treatment options for growth challenges in this specific group of children aged 2 to under 11 years. Participants are divided into groups based on age and gender and randomized to receive different treatments or standard care. The trial includes three groups two experimental groups receiving different doses of Inpegsomatropin injection 140 mcgkgweek or 280 mcgkgweek, administered subcutaneously once a week for 52 weeks, and an active control group receiving recombinant human growth hormone injection at 0.033 mgkgday, administered subcutaneously once daily for 52 weeks. Before treatment, participants undergo a screening period lasting up to 12 weeks. After the 52-week treatment, there is a 5-week post-treatment follow-up to monitor safety and efficacy. Participants will be closely monitored throughout the study with regular assessments of growth velocity, changes in height, bone age, and insulin-like growth factor 1 levels. Safety evaluations will include checking liver and kidney function and monitoring for adverse effects. The main outcome measured is growth velocity after 52 weeks of treatment. The total time involvement for each participant includes screening, treatment, and follow-up periods, ensuring comprehensive evaluation of treatment impact and safety.

Age: 2Years - 11YearsAll GendersPhase 3
49 locations